Certain searches have demonstrated that with disease advancement, the diversity of the pulmonary microbiome in individuals with CF decreases, with opportunistic pathogens, such as P. aeruginosa, predominating [67] Evaluation of changes in the airway microbiome in response to CFTR modulators is thus crucial to improve therapeutic strategies for the management of airway infections [68]. The gene discussed is CFTR; the disease is cystic fibrosis.